Trial Profile

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acoltremon (Primary)
Indications Dry eyes
Focus Therapeutic Use
Acronyms COMET-1
Sponsors Aerie Pharmaceuticals

Most Recent Events

01 Aug 2022 Results presented in an Aerie Pharmaceuticals Media Release.
20 Apr 2022 According to an Aerie Pharmaceuticals media release, data will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022).
15 Sep 2021 According to an Aerie Pharmaceuticals media release, the company will host a conference call and provide accompanying slides to discuss the results from this study at 5:00 p.m. ET today.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com